WILMINGTON, Del., September 15, 2024--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading ...

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according ...

Durvalumab therapy led to a median overall survival of 55.9 months compared with 33.4 months for placebo. Progression-free survival was significantly longer with durvalumab than with placebo, with ...

The positive findings for durvalumab continued with TFST, which was not reached; however, this was 8.3 (95% CI, 4.8-11.8) months for those who did not receive durvalumab.

Durvalumab, an immune checkpoint inhibitor (ICI), was first approved for use in the US as consolidation therapy after cCRT without disease progression in May 2017 5 and in the European Union in ...

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response rates of 77% and 50% and disease control rates of 92% and 93% ...

The estimated mean OS was 55.9 months and 33.4 months for durvalumab and placebo, respectively; 57% of durvalumab-treated patients were alive at 3 years compared with 48% of the placebo group.

The supplemental Biologics License Application for the gastric/GEJ cancer indication is supported by data from the double-blind, placebo-controlled MATTERHORN trial.

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results ...

Immunotherapy is continuing its march: the first trial of an anti-PD-L1 inhibitor in stage 3 non-small cell lung cancer has shown an impressive increase in progression-free survival.

WILMINGTON, Del., February 14, 2025--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered ...